Dorian Therapeutics

Dorian Therapeutics is a biotechnology company based in the U. S. focused on developing innovative therapies aimed at combating cellular aging and enhancing healthspan through advanced cellular rejuvenation technologies. Dorian Therapeutics specializes in anti-senescence technology.

Founded in 2018 and headquartered in San Francisco, US, the company was acquired by Altos Labs, Inc. in an effort to bolster their longevity portfolio. The acquisition took place on May 21, 2025. Dorian Therapeutics is dedicated to advancing cellular rejuvenation programming, focused on restoring cell health and resilience.

Their research targets the biological aspects of cellular aging and stress resistance, employing a multidisciplinary approach for innovative medical applications. The company operates globally, including in North America, Europe, and parts of Asia. Dorian Therapeutics generates revenue by engaging in research agreements and licensing with various stakeholders in the biotechnology and medical sectors. These partnerships facilitate the co-development of applications derived from their core research findings, ensuring mutual benefits for Dorian and its collaborators.

Following its acquisition by Altos Labs, Inc. , Dorian Therapeutics plans to enhance its product offerings with a focus on integrating its anti-senescence technology into Altos' longevity portfolio. The upcoming strategy aims to leverage the latest funding to support product development and market expansion. Specific markets targeted for growth include broader outreach in North America and Europe, with initiatives set for implementation in 2025.